Lara A Dunn1, Nadeem Riaz2, Matthew G Fury3, Sean M McBride2, Loren Michel3, Nancy Y Lee2, Eric J Sherman3, Shrujal S Baxi3, Sofia S Haque4, Nora Katabi5, Richard J Wong6, Han Xiao3, Alan L Ho3, David G Pfister3. 1. Department of Medicine, Head and Neck Oncology, Memorial Sloan Kettering Cancer Center, New York, New York. Electronic address: dunnl1@mskcc.org. 2. Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York. 3. Department of Medicine, Head and Neck Oncology, Memorial Sloan Kettering Cancer Center, New York, New York. 4. Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York. 5. Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York. 6. Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Abstract
PURPOSE: Activation of the PI3K/mTOR signaling pathway is common in head and neck squamous cell carcinoma (HNSCC). BYL719 is an α-specific PI3K inhibitor that is synergistic and efficacious when combined with cetuximab, a Food and Drug Administration-approved radiosensitizing agent in the treatment of HNSCC. The agent independently has been shown to enhance radiosensitivity. This study evaluates the addition of BYL719 to cetuximab and radiation in the treatment of locally advanced HNSCC. METHODS AND MATERIALS: This is a single-institution, phase 1 study. Patients with American Joint Committee on Cancer seventh edition stage III to IVB HNSCC received standard cetuximab (400 mg/m2 intravenous loading dose) before intensity modulated radiation therapy (IMRT) followed by 250 mg/m2 weekly infusions during IMRT. BYL719 was given orally during IMRT in 3 dose levels: (1) 200 mg/d, (2) 250 mg/d, or (3) 300 mg/d in a standard 3 + 3 dose-escalation design. RESULTS: Eleven patients were evaluable. Dose level 2 was the maximum tolerated dose for BYL719. Two patients on dose level 3 had dose-limiting toxicities of oral mucositis that required a dose reduction of BYL719. One patient on dose level 2 had a dose-limiting toxicity of nausea that led to withdrawal of on-study treatment. Related grade 3 or higher adverse events consisted of decreased lymphocyte count, oral mucositis, dysphagia, hyperglycemia, maculopapular rash, and palmar-plantar erythrodysesthesia syndrome. All 11 patients had a complete response on posttreatment imaging, and 10 remain disease free. Of the 8 patients with mutational analysis, 1 had an activating PIK3CA mutation associated with a rapid response on serial intratreatment magnetic resonance imaging scans. CONCLUSIONS: The recommended phase 2 dose of BYL719 is 250 mg/d in combination with cetuximab and IMRT in patients with locally advanced HNSCC. Further evaluation of the addition of BYL719 to the platinum-sparing regimen of cetuximab and IMRT in the treatment of locally advanced HNSCC is warranted.
PURPOSE: Activation of the PI3K/mTOR signaling pathway is common in head and neck squamous cell carcinoma (HNSCC). BYL719 is an α-specific PI3K inhibitor that is synergistic and efficacious when combined with cetuximab, a Food and Drug Administration-approved radiosensitizing agent in the treatment of HNSCC. The agent independently has been shown to enhance radiosensitivity. This study evaluates the addition of BYL719 to cetuximab and radiation in the treatment of locally advanced HNSCC. METHODS AND MATERIALS: This is a single-institution, phase 1 study. Patients with American Joint Committee on Cancer seventh edition stage III to IVB HNSCC received standard cetuximab (400 mg/m2 intravenous loading dose) before intensity modulated radiation therapy (IMRT) followed by 250 mg/m2 weekly infusions during IMRT. BYL719 was given orally during IMRT in 3 dose levels: (1) 200 mg/d, (2) 250 mg/d, or (3) 300 mg/d in a standard 3 + 3 dose-escalation design. RESULTS: Eleven patients were evaluable. Dose level 2 was the maximum tolerated dose for BYL719. Two patients on dose level 3 had dose-limiting toxicities of oral mucositis that required a dose reduction of BYL719. One patient on dose level 2 had a dose-limiting toxicity of nausea that led to withdrawal of on-study treatment. Related grade 3 or higher adverse events consisted of decreased lymphocyte count, oral mucositis, dysphagia, hyperglycemia, maculopapular rash, and palmar-plantar erythrodysesthesia syndrome. All 11 patients had a complete response on posttreatment imaging, and 10 remain disease free. Of the 8 patients with mutational analysis, 1 had an activating PIK3CA mutation associated with a rapid response on serial intratreatment magnetic resonance imaging scans. CONCLUSIONS: The recommended phase 2 dose of BYL719 is 250 mg/d in combination with cetuximab and IMRT in patients with locally advanced HNSCC. Further evaluation of the addition of BYL719 to the platinum-sparing regimen of cetuximab and IMRT in the treatment of locally advanced HNSCC is warranted.
Authors: Moshe Elkabets; Evangelos Pazarentzos; Dejan Juric; Qing Sheng; Raphael A Pelossof; Samuel Brook; Ana Oaknin Benzaken; Jordi Rodon; Natasha Morse; Jenny Jiacheng Yan; Manway Liu; Rita Das; Yan Chen; Angela Tam; Huiqin Wang; Jinsheng Liang; Joseph M Gurski; Darcy A Kerr; Rafael Rosell; Cristina Teixidó; Alan Huang; Ronald A Ghossein; Neal Rosen; Trever G Bivona; Maurizio Scaltriti; José Baselga Journal: Cancer Cell Date: 2015-04-13 Impact factor: 31.743
Authors: Lawrence Koutcher; Eric Sherman; Matthew Fury; Suzanne Wolden; Zhigang Zhang; Qianxing Mo; Laschelle Stewart; Karen Schupak; Daphna Gelblum; Richard Wong; Dennis Kraus; Jatin Shah; Michael Zelefsky; David Pfister; Nancy Lee Journal: Int J Radiat Oncol Biol Phys Date: 2010-10-13 Impact factor: 7.038
Authors: Vivian W Y Lui; Matthew L Hedberg; Hua Li; Bhavana S Vangara; Kelsey Pendleton; Yan Zeng; Yiling Lu; Qiuhong Zhang; Yu Du; Breean R Gilbert; Maria Freilino; Sam Sauerwein; Noah D Peyser; Dong Xiao; Brenda Diergaarde; Lin Wang; Simion Chiosea; Raja Seethala; Jonas T Johnson; Seungwon Kim; Umamaheswar Duvvuri; Robert L Ferris; Marjorie Romkes; Tomoko Nukui; Patrick Kwok-Shing Ng; Levi A Garraway; Peter S Hammerman; Gordon B Mills; Jennifer R Grandis Journal: Cancer Discov Date: 2013-04-25 Impact factor: 39.397
Authors: James A Bonner; Paul M Harari; Jordi Giralt; Nozar Azarnia; Dong M Shin; Roger B Cohen; Christopher U Jones; Ranjan Sur; David Raben; Jacek Jassem; Roger Ove; Merrill S Kies; Jose Baselga; Hagop Youssoufian; Nadia Amellal; Eric K Rowinsky; K Kian Ang Journal: N Engl J Med Date: 2006-02-09 Impact factor: 91.245
Authors: Aviram Mizrachi; Yosi Shamay; Janki Shah; Samuel Brook; Joanne Soong; Vinagolu K Rajasekhar; John L Humm; John H Healey; Simon N Powell; José Baselga; Daniel A Heller; Adriana Haimovitz-Friedman; Maurizio Scaltriti Journal: Nat Commun Date: 2017-02-13 Impact factor: 14.919
Authors: Hisham Mehanna; Max Robinson; Andrew Hartley; Anthony Kong; Bernadette Foran; Tessa Fulton-Lieuw; Matthew Dalby; Pankaj Mistry; Mehmet Sen; Lorcan O'Toole; Hoda Al Booz; Karen Dyker; Rafael Moleron; Stephen Whitaker; Sinead Brennan; Audrey Cook; Matthew Griffin; Eleanor Aynsley; Martin Rolles; Emma De Winton; Andrew Chan; Devraj Srinivasan; Ioanna Nixon; Joanne Grumett; C René Leemans; Jan Buter; Julia Henderson; Kevin Harrington; Christopher McConkey; Alastair Gray; Janet Dunn Journal: Lancet Date: 2018-11-15 Impact factor: 79.321
Authors: Luc G T Morris; Raghu Chandramohan; Lyndsay West; Ahmet Zehir; Debyani Chakravarty; David G Pfister; Richard J Wong; Nancy Y Lee; Eric J Sherman; Shrujal S Baxi; Ian Ganly; Bhuvanesh Singh; Jatin P Shah; Ashok R Shaha; Jay O Boyle; Snehal G Patel; Benjamin R Roman; Christopher A Barker; Sean M McBride; Timothy A Chan; Snjezana Dogan; David M Hyman; Michael F Berger; David B Solit; Nadeem Riaz; Alan L Ho Journal: JAMA Oncol Date: 2017-02-01 Impact factor: 31.777
Authors: V D'Amato; R Rosa; C D'Amato; L Formisano; R Marciano; L Nappi; L Raimondo; C Di Mauro; A Servetto; C Fusciello; B M Veneziani; S De Placido; R Bianco Journal: Br J Cancer Date: 2014-05-13 Impact factor: 7.640
Authors: Giulia Petroni; Lewis C Cantley; Laura Santambrogio; Silvia C Formenti; Lorenzo Galluzzi Journal: Nat Rev Clin Oncol Date: 2021-11-24 Impact factor: 66.675
Authors: Steven Doerstling; David Winski; Evangelia Katsoulakis; Pankaj Agarwal; Pradeep J Poonnen; Jane L Snowdon; Gretchen P Jackson; Dilhan Weeraratne; Michael J Kelley; Vishal Vashistha Journal: J Cancer Res Clin Oncol Date: 2022-09-18 Impact factor: 4.322
Authors: Michelle J Lee; Nan Jin; Jennifer R Grandis; Daniel E Johnson Journal: Biochim Biophys Acta Mol Cell Res Date: 2020-02-19 Impact factor: 4.739
Authors: Yaman Tayyar; Adi Idris; Josif Vidimce; Danyelle Assis Ferreira; Nigel Aj McMillan Journal: Am J Cancer Res Date: 2021-06-15 Impact factor: 6.166